Autopsy report · NCT05574504

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

“PI Decision based on no enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

AdventHealth

Sponsor type

University, hospital or other

Conditions

Metastatic Cancer; Urothelial Carcinoma

Interventions

avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults
  “Business Decision (no enrollment)” (76% match in meaning)
• The Evaluation of the Roles of New Cardiac Imaging in Patients With Chest Pain
  “PI departure from institution + Enrollment Challenges” (73% match in meaning)
• Gut Microbiome and Depression
  “Change in PI and lack of personnel available to complete futher enrollment” (72% match in meaning)
• Use of a Loading Dose of Vancomycin in Pediatric Dosing
  “PI leaving institution, slow enrollment” (67% match in meaning)
• Developing and Validating Fertilit-e
  “PI decision - competing study” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.